<DOC>
	<DOC>NCT01156857</DOC>
	<brief_summary>This is a multicentre, Phase III, efficacy and safety open-label study with PGL4001 10mg once daily for 3 months, blinded towards the administration of progestin or placebo after end of PGL4001 treatment.</brief_summary>
	<brief_title>PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata</brief_title>
	<detailed_description>PGL4001 will be administered daily to all subjects in an open-label manner with no control group. The three months open label treatment period will be followed by a ten day double blind treatment with progestin or matching placebo. Subjects will be randomly assigned to progestin or matching placebo arm with a 1:1 ratio.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Subject is a premenopausal woman aged between 18 and 48 years inclusive. Subject with a Body Mass Index ≥18 and ≤40. Subject with myomatous uterus size &lt; 16 weeks. Subject must have at least one uterine myoma of at least 3 cm diameter in size and no myoma larger than 10 cm diameter diagnosed by ultrasound. Subject complained of strong uterine bleeding. Subject is eligible for hysterectomy or myomectomy. Females of childbearing potential have to practice a nonhormonal method of contraception. Subject has a history of or current uterus, cervix, ovarian or breast cancer. Subject has a history of endometrium hyperplasia or adenocarcinoma in a biopsy performed within the past 6 months or similar lesions in the screening biopsy. Subject has a known severe coagulation disorder. Subject has a history of treatment for myoma with a SPRM, including ulipristal acetate. Subject has abnormal hepatic function at study entry.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>